보고서 요약(국문)

개요
글로벌 생체동등성 연구 시뮬레이터 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
가상 생체동등성 연구(VBE)는 시험 제형과 대조 제형 간의 약동학적 및 임상적 해석의 유사성과 차이점을 평가할 수 있으며, 이는 시험관 내(in vitro), 컴퓨터 시뮬레이션(in silico), 생체 내(in vivo) 간의 변환적 연관성을 기반으로 합니다. 가상 생체동등성 연구를 통해 임상 연구에서 얻은 핵심 정보를 활용할 수 있으며, 이는 신약 및 제네릭 의약품 개발을 가속화하는 데 도움이 됩니다.
시장 동향: 성장 동인 및 제약 요인
제네릭 의약품 수요 증가
전 세계 시장은 예측 기간 동안 제네릭 의약품 수요 증가로 인해 성장이 촉진될 것으로 예상됩니다. 미국 국립보건원(NIH)에 따르면, 미국 소비자들은 제네릭 의약품에 연간 약 1,030억 달러를 지출하고 있습니다. 미국 식품의약국(FDA)의 승인을 받은 제네릭 의약품은 고가의 브랜드 제품을 거의 완벽하게 대체할 수 있는 것으로 여겨집니다. 또한, 미국 FDA에 따르면 미국에서 처방되는 의약품의 90%가 제네릭 의약품입니다.
더불어 감염성 질환과 만성 질환의 증가, 그리고 활발한 연구 활동은 예측 기간 동안 세계 시장 성장에 기여할 것으로 예상되는 주요 요인입니다.
생체동등성 연구 관련 문제점
높은 변동성, 흡수율이 매우 낮은 약물, 고유한 기준선을 가진 내인성 물질 등 생체동등성 연구와 관련된 문제점들은 예측 기간 동안 세계 시장 성장을 저해할 것으로 예상됩니다. 또한, 높은 비용과 숙련된 전문가 부족도 예측 기간 동안 세계 시장 성장을 저해하는 추가적인 요인입니다.
세분화 분석
세계 생체동등성 연구 시뮬레이터 시장은 연구 유형, 응용 분야, 최종 사용자 및 지역별로 세분화됩니다.

생체이용률 연구 유형이 시장을 주도할 것으로 예상됩니다.
생체이용률 연구 유형은 제품 출시 증가로 인해 예측 기간 동안 전 세계 시장을 주도할 것으로 예상됩니다. 예를 들어, 제약, 생명공학, 화학 및 소비재 산업을 위한 모델링 및 시뮬레이션 솔루션의 주요 공급업체인 Simulations Plus, Inc.는 2021년 2월에 자사의 대표적인 생리 기반 생물약제학(PBBM)/약물동태학(PBPK) 모델링 프로그램인 GastroPlus의 버전 9.8.1을 출시했습니다. 또한, 2021년 10월에는 동일 프로그램의 버전 9.8.2를 출시한다고 발표했습니다.

지리적 분석
북미 지역이 세계 시장을 주도할 것으로 예상됩니다.
북미 지역에서는 생리학적 기반 생물약제학/약물동태학(PBBM/PBPK) 모델링 워크플로우에 대한 최적의 방법을 검증하고 정의하기 위한 정부 보조금이 증가하고 있으며, 이는 규제 기관의 생물학적 면제(biowaiver)를 지원하기 위한 가상 생체동등성(VBE) 조사 시뮬레이션에 활용됩니다. 이러한 추세에 따라 북미 지역은 예측 기간 동안 세계 시장을 주도할 것으로 예상됩니다.
예를 들어, 제약 안전성 및 효능 분야의 모델링 및 시뮬레이션 소프트웨어 및 서비스 제공업체인 Simulations Plus, Inc.는 2022년 11월, 미국 식품의약국(FDA)으로부터 플로리다 대학교 약학대학과의 공동 제안을 통해 흡입 약물의 폐 흡수 및 조직 잔류를 이해하고 예측하기 위한 체외 및 (병리)생리학 기반 약물동태학(PBPK) 프로토타입 개발을 위한 새로운 후원 계약을 체결했습니다. 2023년 9월, Simulations Plus, Inc.는 미국 식품의약국(FDA)으로부터 새로운 연구 지원금을 받았습니다.

COVID-19 영향 분석
COVID-19 팬데믹은 신약 개발에서 속도와 안전성의 중요성을 강조했습니다. 생체동등성 연구 시뮬레이터는 연구자들이 기존 약물의 용도 변경을 평가하고, 약물 상호작용을 예측하며, 점점 더 다양한 투여 경로를 통해 가상 생체동등성 평가를 수행할 수 있도록 지원합니다. 따라서 팬데믹은 생체동등성 연구 시뮬레이터의 도입을 증가시켜 세계 시장에 긍정적인 영향을 미쳤습니다.

시장 세분화
연구 유형별
• 생체이용률 연구
• 단회 투여 연구
• 다회 투여 연구
• 비교 평가변수 연구
적용 분야별
• 심혈관 질환
• 종양학
• 중추신경계 질환
• 감염성 질환
• 기타
최종 사용자별
• 제약 회사
• 연구 기관
• 임상 연구 위탁 기관
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발 사항
• 제약, 생명공학, 화학 및 소비재 산업을 위한 모델링 및 시뮬레이션 솔루션의 선도적인 공급업체인 Simulations Plus, Inc.는 2020년 10월 생리 기반 생물약제학을 위한 주력 플랫폼 버전 9.8을 출시했습니다. (PBBM) / 약물동태학(PBPK) 모델링, GastroPlus.

• 2021년 1월, 생체 시뮬레이션 분야의 글로벌 리더인 Certara, Inc.는 생리 기반 약물동태학(PBPK) 시뮬레이터 플랫폼 Simcyp 버전 20을 출시했습니다.

경쟁 환경
시장의 주요 글로벌 업체로는 Simulations Plus, Inc., Certara, Inc., Pumas-AI, Inc., BioPharma Services Inc., Open Systems Pharmacology 등이 있습니다.

보고서 구매 이유

• 연구 유형, 응용 분야, 최종 사용자 및 지역별 글로벌 생체동등성 연구 시뮬레이터 시장 세분화를 시각화하고 주요 상업적 자산 및 업체를 파악하기 위함입니다.

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별하기 위함입니다.

• 모든 세그먼트를 포함한 생체동등성 연구 시뮬레이터 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트가 제공됩니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서가 제공됩니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 엑셀 파일로 제공합니다.
글로벌 생체동등성 연구 시뮬레이터 시장 보고서는 약 46개의 표, 55개의 그림, 180페이지 분량으로 구성됩니다.
2023년 목표 고객
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Bioequivalence Studies Simulators market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Virtual bioequivalence studies (VBE) can evaluate the resemblance and probable discrepancies in pharmacokinetic and clinical interpretation between test and reference formulations established on the translational association between in vitro, in silico, and in vivo. The essential information from clinical investigations can be provided with the aid of virtual bioequivalence investigation, which intends to hasten up the design of novel and generic medications.
Market Dynamics: Drivers & Restraints
Increasing Demand for Generic Drugs
The global market growth is expected to receive a boost due to the increasing demand for generic drugs during the forecast period. As per the National Institutes of Health (NIH), American consumers spend around $103 billion per year on generic drugs. Upon receiving approval from the Food and Drug Administration (FDA), generic drugs are considered to be almost perfect substitutes for the high-priced branded products they replicate. Furthermore, according to the United States Food and Drug Administration, 9 out of 10 prescriptions filled in the United States are for generic drugs.
Additionally, the rise in infectious and chronic diseases and growing research activities are among other factors that are expected to contribute to the global market growth during the forecast period.
Problems Associated with Bioequivalence Studies
The problems associated with bioequivalence studies such as high variability, very poorly absorbed drugs, and endogenous substances with their own baseline among others are expected to hamper the global market growth during the forecast period. Furthermore, high cost and a deficient number of skilled professionals are among the additional factors hampering the global market growth during the forecast period.
Segment Analysis
The global bioequivalence studies simulators market is segmented based on study type, application, end user and region.
Bioavailability Study Type is Expected to Dominate Market
The bioavailability study type is expected to dominate the global market during the forecast period due to the increase in product introductions. For instance in February 2021, Simulations Plus, Inc., a top provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, released the version 9.8.1 of its flagship physiologically based biopharmaceutics (PBBM)/ pharmacokinetics (PBPK) modeling program, GastroPlus, . Additionally, in October 2021, the company announced the release of version 9.8.2 of the same program.
Geographical Analysis
North America is Expected to Dominate the Global Market
Owing to the increasing grants from the government to validate and define best practices for physiologically based biopharmaceutics/pharmacokinetics (PBBM/PBPK) modeling workflows to simulate virtual bioequivalence (VBE) investigations in support of regulatory biowaivers in North America the region is estimated to dominate the global market during the forecast period.
For instance, in November 2022, Simulations Plus, Inc., a top provider of modeling and simulation software and services for pharmaceutical safety and efficacy, acquired a new sponsored contract from the U.S. Food and Drug Administration (FDA) as a collaborative proposal with the University of Florida’s College of Pharmacy to promote in vitro and (patho)physiology-based pharmacokinetics (PBPK) prototypes to comprehend and predict pulmonary absorption and tissue retention of inhaled drugs. Again, in September 2023, Simulations Plus, Inc. obtained a new funded grant from the U.S. Food and Drug Administration (FDA).
COVID-19 Impact Analysis
The COVID-19 pandemic has underscored the importance of speed and safety in drug development. The bioequivalence studies simulators are providing researchers with the ability to evaluate repurposing of existing drugs, predict drug-drug interactions, and perform virtual bioequivalence assessments with an increasing variety of dosing routes. Thus, the pandemic has led to increase in the adoption of the bioequivalence studies simulators, positively impacting the global market.
Market Segmentation
By Study Type
• Bioavailability Studies
• Single Dose Studies
• Multidose Studies
• Comparative End Point Studies
By Application
• Cardiovascular Disease
• Oncology
• CNS Disorders
• Infectious Diseases
• Other
By End User
• Pharmaceutical Companies
• Research Institutes
• Contract Research Organizations
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In October 2020, Simulations Plus, Inc., the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, introduced version 9.8 of its flagship platform for physiologically based biopharmaceutics (PBBM) / pharmacokinetic (PBPK) modeling, GastroPlus.
• In January 2021, Certara, Inc., the global leader in biosimulation, introduced version 20 of its Simcyp Physiologically-based Pharmacokinetic (PBPK) Simulator platform.
Competitive Landscape
The major global players in the market include Simulations Plus, Inc., Certara, Inc., Pumas-AI, Inc., BioPharma Services Inc., and Open Systems Pharmacology among others.
Why Purchase the Report?
• To visualize the global bioequivalence studies simulators market segmentation based on study type, application, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of bioequivalence studies simulators market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global bioequivalence studies simulators market report would provide approximately 46 tables, 55 figures and 180 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Study Type
3.2. Snippet by Application
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Demand for Generic Drugs
4.1.1.2. YY
4.1.2. Restraints
4.1.2.1. Problems Associated
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Pricing Analysis
5.3. Regulatory Analysis
5.4. Patent Analysis
5.5. Technology Trend
5.6. Unmet Need
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Study Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
7.1.2. Market Attractiveness Index, By Study Type
7.2. Bioavailability Studies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Single Dose Studies
7.4. Multidose Studies
7.5. Comparative End Point Studies
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Cardiovascular Disease*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Oncology
8.4. CNS Disorders
8.5. Infectious Diseases
8.6. Other
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospital*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Research Institutes
9.4. Contract Research Organizations
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Simulations Plus, Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Certara, Inc.
12.3. Pumas-AI, Inc., Inc.
12.4. BioPharma Services Inc.
12.5. OPEN SYSTEMS PHARMACOLOGY
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Simulations Plus, Inc., 4.	Key Developments, Certara, Inc., Pumas-AI, Inc., Inc., BioPharma Services Inc., OPEN SYSTEMS PHARMACOLOGY

표 목록 (Tables)

List of Tables

Table 1 Global Bioequivalence Studies Simulators Market Value, By Study Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Bioequivalence Studies Simulators Market Value, By Application, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Bioequivalence Studies Simulators Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Bioequivalence Studies Simulators Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Bioequivalence Studies Simulators Market Value, By Study Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Bioequivalence Studies Simulators Market Value, By Study Type, 2021-2030 (US$ Million)

Table 7 Global Bioequivalence Studies Simulators Market Value, By Application, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Bioequivalence Studies Simulators Market Value, By Application, 2021-2030 (US$ Million)

Table 9 Global Bioequivalence Studies Simulators Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Bioequivalence Studies Simulators Market Value, By End User, 2021-2030 (US$ Million)

Table 11 Global Bioequivalence Studies Simulators Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Bioequivalence Studies Simulators Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Bioequivalence Studies Simulators Market Value, By Study Type, 2021-2030 (US$ Million)

Table 14 North America Bioequivalence Studies Simulators Market Value, By Application, 2021-2030 (US$ Million)

Table 15 North America Bioequivalence Studies Simulators Market Value, By End User, 2021-2030 (US$ Million)

Table 16 North America Bioequivalence Studies Simulators Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Bioequivalence Studies Simulators Market Value, By Study Type, 2021-2030 (US$ Million)

Table 18 South America Bioequivalence Studies Simulators Market Value, By Application, 2021-2030 (US$ Million)

Table 19 South America Bioequivalence Studies Simulators Market Value, By End User, 2021-2030 (US$ Million)

Table 20 South America Bioequivalence Studies Simulators Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Bioequivalence Studies Simulators Market Value, By Study Type, 2021-2030 (US$ Million)

Table 22 Europe Bioequivalence Studies Simulators Market Value, By Application, 2021-2030 (US$ Million)

Table 23 Europe Bioequivalence Studies Simulators Market Value, By End User, 2021-2030 (US$ Million)

Table 24 Europe Bioequivalence Studies Simulators Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Bioequivalence Studies Simulators Market Value, By Study Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Bioequivalence Studies Simulators Market Value, By Application, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Bioequivalence Studies Simulators Market Value, By End User, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Bioequivalence Studies Simulators Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Bioequivalence Studies Simulators Market Value, By Study Type, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Bioequivalence Studies Simulators Market Value, By Application, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Bioequivalence Studies Simulators Market Value, By End User, 2021-2030 (US$ Million)

Table 32 Simulations Plus, Inc.: Overview

Table 33 Simulations Plus, Inc.: Product Portfolio

Table 34 Simulations Plus, Inc.: Key Developments

Table 35 Certara, Inc.: Overview

Table 36 Certara, Inc.: Product Portfolio

Table 37 Certara, Inc.: Key Developments

Table 38 Pumas-AI, Inc., Inc.: Overview

Table 39 Pumas-AI, Inc., Inc.: Product Portfolio

Table 40 Pumas-AI, Inc., Inc.: Key Developments

Table 41 BioPharma Services Inc.: Overview

Table 42 BioPharma Services Inc.: Product Portfolio

Table 43 BioPharma Services Inc.: Key Developments

Table 44 OPEN SYSTEMS PHARMACOLOGY: Overview

Table 45 OPEN SYSTEMS PHARMACOLOGY: Product Portfolio

Table 46 OPEN SYSTEMS PHARMACOLOGY: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 2 Global Bioequivalence Studies Simulators Market Share, By Study Type, 2022 & 2030 (%)

Figure 3 Global Bioequivalence Studies Simulators Market Share, By Application, 2022 & 2030 (%)

Figure 4 Global Bioequivalence Studies Simulators Market Share, By End User, 2022 & 2030 (%)

Figure 5 Global Bioequivalence Studies Simulators Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Bioequivalence Studies Simulators Market Y-o-Y Growth, By Study Type, 2022-2030 (%)

Figure 7 Bioavailability Studies Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 8 Single Dose Studies Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 9 Multidose Studies Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 10 Comparative End Point Studies Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 11 Global Bioequivalence Studies Simulators Market Y-o-Y Growth, By Application, 2022-2030 (%)

Figure 12 Cardiovascular Disease Application in Global Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 13 Oncology Application in Global Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 14 CNS Disorders Application in Global Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 15 Infectious Diseases Application in Global Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 16 Other Application in Global Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 17 Global Bioequivalence Studies Simulators Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 18 Pharmaceutical Companies End User in Global Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 19 Research Institutes End User in Global Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 20 Contract Research Organizations End User in Global Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 21 Global Bioequivalence Studies Simulators Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 22 North America Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 23 Asia-Pacific Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 24 Europe Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 25 South America Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 26 Middle East and Africa Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 27 North America Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 28 North America Bioequivalence Studies Simulators Market Share, By Study Type, 2022 & 2030 (%)

Figure 29 North America Bioequivalence Studies Simulators Market Share, By Application, 2022 & 2030 (%)

Figure 30 North America Bioequivalence Studies Simulators Market Share, By End User, 2022 & 2030 (%)

Figure 31 North America Bioequivalence Studies Simulators Market Share, By Country, 2022 & 2030 (%)

Figure 32 South America Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 33 South America Bioequivalence Studies Simulators Market Share, By Study Type, 2022 & 2030 (%)

Figure 34 South America Bioequivalence Studies Simulators Market Share, By Application, 2022 & 2030 (%)

Figure 35 South America Bioequivalence Studies Simulators Market Share, By End User, 2022 & 2030 (%)

Figure 36 South America Bioequivalence Studies Simulators Market Share, By Country, 2022 & 2030 (%)

Figure 37 Europe Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 38 Europe Bioequivalence Studies Simulators Market Share, By Study Type, 2022 & 2030 (%)

Figure 39 Europe Bioequivalence Studies Simulators Market Share, By Application, 2022 & 2030 (%)

Figure 40 Europe Bioequivalence Studies Simulators Market Share, By End User, 2022 & 2030 (%)

Figure 41 Europe Bioequivalence Studies Simulators Market Share, By Country, 2022 & 2030 (%)

Figure 42 Asia-Pacific Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 43 Asia-Pacific Bioequivalence Studies Simulators Market Share, By Study Type, 2022 & 2030 (%)

Figure 44 Asia-Pacific Bioequivalence Studies Simulators Market Share, By Application, 2022 & 2030 (%)

Figure 45 Asia-Pacific Bioequivalence Studies Simulators Market Share, By End User, 2022 & 2030 (%)

Figure 46 Asia-Pacific Bioequivalence Studies Simulators Market Share, By Country, 2022 & 2030 (%)

Figure 47 Middle East & Africa Bioequivalence Studies Simulators Market Value, 2021-2030 (US$ Million)

Figure 48 Middle East & Africa Bioequivalence Studies Simulators Market Share, By Study Type, 2022 & 2030 (%)

Figure 49 Middle East & Africa Bioequivalence Studies Simulators Market Share, By Application, 2022 & 2030 (%)

Figure 50 Middle East & Africa Bioequivalence Studies Simulators Market Share, By End User, 2022 & 2030 (%)

Figure 51 Simulations Plus, Inc.: Financials

Figure 52 Certara, Inc.: Financials

Figure 53 Pumas-AI, Inc., Inc.: Financials

Figure 54 BioPharma Services Inc.: Financials

Figure 55 OPEN SYSTEMS PHARMACOLOGY: Financials

글로벌 생체동등성 연구 시뮬레이터 시장 – 2023-2030

Global Bioequivalence Studies Simulators Market - 2023-2030